We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Circulating Phosphorylated Tau Proteins Linked to Postoperative Delirium

By LabMedica International staff writers
Posted on 11 Jul 2022
Print article
Image: Phosphorylation (yellow) of tau proteins (red-orange) by kinases (violet) leads to the formation of Alzheimer’s disease biomarkers that are also associated with postoperative delirium (Photo courtesy of 123rf.com)
Image: Phosphorylation (yellow) of tau proteins (red-orange) by kinases (violet) leads to the formation of Alzheimer’s disease biomarkers that are also associated with postoperative delirium (Photo courtesy of 123rf.com)

A recent study found that two Alzheimer’s disease biomarkers that circulate in the blood may be used to predict the incidence and severity of postoperative delirium.

Delirium is an acute change in cognition and attention, which may include alterations in consciousness and disorganized thinking. While delirium may affect any age group, it is most common in older patients, especially those with preexisting cognitive impairment. Patients with delirium after surgery recover more slowly than those without delirium and, as a result, have increased length of stay and hospital costs. The measured incidence of postoperative delirium varies with the type of surgery, the urgency of surgery, and the type and sensitivity of the delirium assessment. While generally considered a short-term condition, delirium can persist for months and is associated with poor cognitive and functional outcomes beyond the immediate postoperative period.

Previous clinical studies have demonstrated a strong association between Alzheimer’s disease and delirium. On this basis, investigators at Harvard University’s Massachusetts General Hospital (Boston, USA) and colleagues at the biotechnology company NanoMosaic (Woburn, MA, USA) sought to determine whether Alzheimer’s disease biomarkers in the blood were associated with postoperative delirium.

For this study, the investigators used NonoMosaic’s nanoneedle technology to measure preoperative levels of the phosphorylated tau proteins Tau-PT217 and Tau-PT181 in plasma samples obtained from 139 patients (65 years old or older) who had a knee replacement, hip replacement, or laminectomy. Presence and severity of postoperative delirium were assessed in the patients.

Results revealed that of the 139 participants, 18 (13%) developed postoperative delirium. The patients who developed postoperative delirium were found to have higher preoperative plasma concentrations of Tau-PT217 and Tau-PT181 than those who did not. Preoperative plasma concentrations of Tau-PT217 or Tau-PT181 were independently associated with postoperative delirium after adjusting for age, education, and preoperative mental state. Overall, Tau-PT217 was a stronger indicator of postoperative delirium than was Tau-PT181.

“These outcomes help diagnosis of postoperative delirium; identify intermediate outcomes that could facilitate clinical studies; and elucidate the insight into potential mechanisms of postoperative delirium, ultimately leading to better and safer postoperative outcomes in patients,” said senior author Dr. Zhongcong Xie, professor of anesthesia at Harvard Medical School. “These data also suggest that tau phosphorylation, contributes, at least partly, to the development of postoperative delirium.”

The study was published in the July 6, 2022, online edition of the journal Annals of Surgery.

Related Links:
Massachusetts General Hospital 
NanoMosaic 

 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.